Agilent (A) Stock Forecast & Price Target

Compare

3,317 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

A Analyst Ratings

Strong Buy

12 Buy

1 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Agilent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

A Stock 12 Month Forecast

Average Price Target

$163.62

▲(38.53% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is $163.62 with a high forecast of $185.00 and a low forecast of $150.00. The average price target represents a 38.53% change from the last price of $118.11.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"104":"$104","145":"$145","186":"$186","124.5":"$124.5","165.5":"$165.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":185,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$185.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":163.62,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$163.62</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$150.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[104,124.5,145,165.5,186],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.17,123.31076923076924,128.45153846153846,133.59230769230768,138.73307692307694,143.87384615384616,149.01461538461538,154.1553846153846,159.29615384615386,164.43692307692308,169.5776923076923,174.71846153846155,179.85923076923078,{"y":185,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.17,121.66615384615385,125.16230769230769,128.65846153846155,132.1546153846154,135.65076923076924,139.1469230769231,142.64307692307693,146.13923076923078,149.63538461538462,153.13153846153847,156.6276923076923,160.12384615384616,{"y":163.62,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.17,120.61846153846155,123.06692307692308,125.51538461538462,127.96384615384616,130.4123076923077,132.86076923076922,135.30923076923077,137.7576923076923,140.20615384615385,142.6546153846154,145.1030769230769,147.55153846153846,{"y":150,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":126.898,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.379,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.834,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.397,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":119.994,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.07,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.184,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.332,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":146.098,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.832,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.827,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.39,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.17,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$185.00

Average Price Target$163.62

Lowest Price Target$150.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kallum Titchmarsh

Morgan Stanley

$180→$160

Buy

35.47%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Dyne Therapeutics (NASDAQ: DYN) and Agilent (NYSE: A)

Evie Koslosky

Goldman Sachs

$170→$150

Buy

27.00%

Upside

Reiterated

02/27/26

Agilent price target lowered to $150 from $170 at Goldman SachsAgilent price target lowered to $150 from $170 at Goldman Sachs

Daniel Brennan

TD Cowen

$170→$157

Buy

32.93%

Upside

Assigned

02/26/26

Weather-Driven Miss Masks Underlying Strength at Agilent, Creating a Buy Opportunity

Brandon Couillard

Wells Fargo

$165

Buy

39.70%

Upside

Reiterated

02/26/26

Agilent (A) Receives a Buy from Wells Fargo

Dan Leonard

UBS

$180→$165

Buy

39.70%

Upside

Reiterated

02/26/26

Agilent price target lowered to $165 from $180 at UBSAgilent price target lowered to $165 from $180 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$165→$155

Buy

31.23%

Upside

Reiterated

02/26/26

Agilent price target lowered to $155 from $165 at BairdAgilent price target lowered to $155 from $165 at Baird

Michael Ryskin

Bank of America Securities

$165→$150

Hold

27.00%

Upside

Reiterated

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Carlsmed, Inc. (NASDAQ: CARL) and Agilent (NYSE: A)

Patrick B Donnelly

Citi

$185

Buy

56.63%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)

Daniel Arias

Stifel Nicolaus

$170

Buy

43.93%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Xencor (NASDAQ: XNCR) and Pennant Group (NASDAQ: PNTG)

Casey Woodring

J.P. Morgan

$180

Buy

52.40%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Agilon Health (NYSE: AGL) and Sarepta Therapeutics (NASDAQ: SRPT)

Luke Sergott

Barclays

$165→$150

Buy

27.00%

Upside

Reiterated

02/26/26

Agilent (A) Gets a Buy from Barclays

Sidharth Sahoo

HSBC

$180

Buy

52.40%

Upside

Initiated

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

$155→$160

Buy

35.47%

Upside

Upgraded

01/05/26

Agilent upgraded to Outperform from In Line at Evercore ISIAgilent upgraded to Outperform from In Line at Evercore ISI

Tycho Peterson

Jefferies

$130

Hold

10.07%

Upside

Reiterated

10/17/25

Agilent (A) Gets a Hold from Jefferies

Natalya Davies

Rothschild & Co Redburn

$165

Buy

39.70%

Upside

Initiated

10/08/25

Agilent initiated with a Buy at Rothschild & Co RedburnAgilent initiated with a Buy at Rothschild & Co Redburn

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kallum Titchmarsh

Morgan Stanley

$180→$160

Buy

35.47%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Dyne Therapeutics (NASDAQ: DYN) and Agilent (NYSE: A)

Evie Koslosky

Goldman Sachs

$170→$150

Buy

27.00%

Upside

Reiterated

02/27/26

Agilent price target lowered to $150 from $170 at Goldman SachsAgilent price target lowered to $150 from $170 at Goldman Sachs

Daniel Brennan

TD Cowen

$170→$157

Buy

32.93%

Upside

Assigned

02/26/26

Weather-Driven Miss Masks Underlying Strength at Agilent, Creating a Buy Opportunity

Brandon Couillard

Wells Fargo

$165

Buy

39.70%

Upside

Reiterated

02/26/26

Agilent (A) Receives a Buy from Wells Fargo

Dan Leonard

UBS

$180→$165

Buy

39.70%

Upside

Reiterated

02/26/26

Agilent price target lowered to $165 from $180 at UBSAgilent price target lowered to $165 from $180 at UBS

Catherine Ramsey Schulte

Robert W. Baird

$165→$155

Buy

31.23%

Upside

Reiterated

02/26/26

Agilent price target lowered to $155 from $165 at BairdAgilent price target lowered to $155 from $165 at Baird

Michael Ryskin

Bank of America Securities

$165→$150

Hold

27.00%

Upside

Reiterated

02/26/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Carlsmed, Inc. (NASDAQ: CARL) and Agilent (NYSE: A)

Patrick B Donnelly

Citi

$185

Buy

56.63%

Upside

Reiterated

02/26/26

Analysts Conflicted on These Healthcare Names: PROCEPT BioRobotics (NASDAQ: PRCT), Soleno Therapeutics (NASDAQ: SLNO) and Agilent (NYSE: A)

Daniel Arias

Stifel Nicolaus

$170

Buy

43.93%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Xencor (NASDAQ: XNCR) and Pennant Group (NASDAQ: PNTG)

Casey Woodring

J.P. Morgan

$180

Buy

52.40%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A), Agilon Health (NYSE: AGL) and Sarepta Therapeutics (NASDAQ: SRPT)

Luke Sergott

Barclays

$165→$150

Buy

27.00%

Upside

Reiterated

02/26/26

Agilent (A) Gets a Buy from Barclays

Sidharth Sahoo

HSBC

$180

Buy

52.40%

Upside

Initiated

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

$155→$160

Buy

35.47%

Upside

Upgraded

01/05/26

Agilent upgraded to Outperform from In Line at Evercore ISIAgilent upgraded to Outperform from In Line at Evercore ISI

Tycho Peterson

Jefferies

$130

Hold

10.07%

Upside

Reiterated

10/17/25

Agilent (A) Gets a Hold from Jefferies

Natalya Davies

Rothschild & Co Redburn

$165

Buy

39.70%

Upside

Initiated

10/08/25

Agilent initiated with a Buy at Rothschild & Co RedburnAgilent initiated with a Buy at Rothschild & Co Redburn

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

3 Months

xxx

Success Rate

17/26 ratings generated profit

Average Return

+4.19%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.38% of your transactions generating a profit, with an average return of +4.19% per trade.

1 Year

Brandon CouillardWells Fargo

Success Rate

29/41 ratings generated profit

Average Return

+15.73%

reiterated a buy rating 10 days ago

Copying Brandon Couillard's trades and holding each position for 1 Year would result in 70.73% of your transactions generating a profit, with an average return of +15.73% per trade.

2 Years

xxx

Success Rate

17/26 ratings generated profit

Average Return

+28.11%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 65.38% of your transactions generating a profit, with an average return of +28.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, A has received 23 Buy Ratings, 48 Hold Ratings, and 0 Sell Ratings. A average Analyst price target in the past 3 months is 163.62.

Each month's total comprises the sum of three months' worth of ratings.

A Financial Forecast

A Earnings Forecast

Next quarter’s earnings estimate for A is $1.41 with a range of $1.38 to $1.42. The previous quarter’s EPS was $1.36. A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Sales Forecast

Next quarter’s sales forecast for A is $1.80B with a range of $1.78B to $1.81B. The previous quarter’s sales results were $1.80B. A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year A has Performed in-line its overall industry.

A Stock Forecast FAQ

What is A’s average 12-month price target, according to analysts?

Based on analyst ratings, Agilent’s 12-month average price target is 163.62.

What is A’s upside potential, based on the analysts’ average price target?

Agilent has 38.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is A a Buy, Sell or Hold?

Agilent has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.

What is Agilent’s price target?

The average price target for Agilent is 163.62. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $185.00 ,the lowest forecast is $150.00. The average price target represents 38.53% Increase from the current price of $118.11.

What do analysts say about Agilent?

Agilent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of A?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Agilent (A) Stock Forecast & Price Target

A Analyst Ratings

A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Agilent

A Analyst Recommendation Trends

A Financial Forecast

A Earnings Forecast

A Sales Forecast

A Stock Forecast FAQ

Detailed List of Analyst Forecasts